©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
HER4-mediated Biological and Biochemical Properties in NIH 3T3 Cells
EVIDENCE FOR HER1-HER4 HETERODIMERS (*)

(Received for publication, June 20, 1995; and in revised form, October 27, 1995)

Bruce D. Cohen (§) Janell M. Green Linda Foy H. Perry Fell

From the Molecular Immunology Department, Bristol-Myers Squibb, Pharmaceutical Research Institute, Seattle, Washington 98121

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

The EGF receptor family of tyrosine kinase growth factor receptors is expressed in a variety of cell types and has been implicated in the progression of certain human adenocarcinomas. The most recent addition to this family of receptors, HER4, was expressed in NIH 3T3 cells to determine its biological and biochemical characteristics. Cells expressing HER4 were responsive to heregulin beta2 as demonstrated by an increase in HER4 tyrosine phosphorylation and ability to form foci on a cell monolayer. HER4 exhibited in vitro kinase activity and was able to phosphorylate the regulatory subunit of phosphatidylinositol 3-kinase and SHC. Peptide competition studies identified tyrosine 1056 of HER4 as the phosphatidylinositol 3-kinase binding site and tyrosines 1188 and 1242 as two potential SHC binding sites. Interestingly, transfection of HER4 into NIH 3T3 cells conferred responsiveness to EGF with respect to colony formation in soft agar. It was also found that in response to heregulin beta2, endogenous murine HER1 or transfected human HER1 became phosphorylated when HER4 was present. This demonstrates that HER1 and HER4 can exist in a heterodimer complex and likely activate each other by transphosphorylation.


INTRODUCTION

The human epidermal growth factor receptor (HER) (^1)family of type I receptor tyrosine kinases has been linked to the progression of certain human adenocarcinomas. The mechanism by which these receptors function with respect to tumor development is thought to involve overproduction of the gene product resulting from an increase in gene copy number or expression(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12) . Receptor overexpression often correlates with a high level of constitutive tyrosine kinase activity, and this activity is thought to promote signals leading to uncontrolled cell growth (13) .

Several ligands that bind to and stimulate the kinase activity of the HER family members have been identified and are classified as EGF-like ligands. EGF, amphiregulin, betacellulin, and transforming growth factor alpha are specific for HER1(14) . Heregulin and its rat homologue neu differentiation factor, are a subfamily of the EGF-like ligands that have been shown to bind to and activate both HER3 and HER4 (15, 16, 17, 18, 19, 20, 21, 22) . The molecular characterization of a HER2 ligand has not been reported; however, a number of factors have been shown to activate HER2 tyrosine kinase activity specifically(23, 24, 25) .

Activation of the EGF receptor family of tyrosine kinase receptors, using EGFR as the model, is thought to involve the binding of ligand and subsequent homodimerization of the receptor resulting in a conformational change and activation of the intrinsic tyrosine kinase activity(58) . Recent advances suggest that a more complex mechanism of HER activation can occur. Heregulin has been shown to bind and stimulate both HER3 and HER4(15, 26) . Thus, the signaling repertoire of any one ligand can be multifaceted depending upon the cellular receptor expression patterns, potentially allowing the same ligand to deliver distinct downstream signals. Further, ligand-induced receptor activation in the HER family is not limited to homodimerization, for it has been demonstrated that many of the HER family members can associate with and activate each other(15, 27, 28, 29, 30) . HER2 has been shown to heterodimerize with HER1, HER3, and HER4, and EGF stimulation of HER1 has been shown to activate HER3 signaling(31) . Therefore, the signaling of receptors by multifunctional ligands on homoreceptor and heteroreceptor complexes could result in a multiplicity of downstream signaling events.

Activation of growth factor receptors results in the transmission of stimulatory signals from the outside to the inside of the cell. This process makes use of intracellular proteins, or targets, that contain Src homology region 2 (SH2) domains that recognize and bind to the activated receptor(32, 33) . A number of these proteins have been identified and shown to interact with membrane-associated and cytoplasmic tyrosine kinases(32, 34, 35, 36) . The specificity of their binding is dictated by receptor sequences that flank a specific phosphotyrosine residue(33, 37) . Since the HER family members are similar but not identical in their amino acid sequence, an expected diversity of associations with different SH2-containing proteins has been demonstrated. HER1 has been shown to associate with phospholipase C-, SHC, and Grb2(13, 38, 39, 40, 41, 42) . HER2 can associate with phospholipase C-, SHC, and Ras-GTPase activating protein(43, 44, 45) . HER3 has recently been shown to activate PI 3-kinase(31, 41, 46) .

We have focused on characterizing the newest member of the HER family, HER4, with regard to its biological activity and activation of downstream targets. To this end, a collection of HER4-expressing 3T3 cell lines has been generated and used to assay the biological and enzymatic activities of this receptor.


EXPERIMENTAL PROCEDURES

Cell Culture

NIH 3T3 clone 7 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (Life Technologies, Inc.) at 37° in 5% CO(2)(47) . Cells expressing receptors were produced by pooling G418 resistant colonies from cultures that had been cotransfected with the pSV2neo plasmid and maintained in 500 µg/ml G418. Transfections were done using Lipofectamine (Life Technologies, Inc.). HER2 and HER4 plasmid construction have been described previously(15) . Cell lines expressing both HER1 and HER4 were produced by transfection of HER1-expressing plasmid into the HER4 cell line and selecting clones by histidinol selection. Clonal lines were isolated and lines expressing similar amounts of HER4 were used.

Ligands

Heregulin beta2 used in all assays was synthesized as described previously(48) . Briefly, the EGF domain of heregulin beta2 was fused to the Fc portion of a human IgG1 gene, and this construct was transfected and expressed in COS cells. The heregulin portion of the purified IgG1 fusion was cleaved away from the Fc domain with thrombin and purified.

Focus-forming Assay

Transfected NIH 3T3 clone 7 cells were trypsinized, and approximately 500 cells were mixed with 10^5 progenitor 3T3 clone 7 cells. The following day, EGF or heregulin beta2 was added at 20 µg/ml, and the cells were fed on a 2-day schedule. Cells were stained after 7-10 days with methylene blue/carboyl fuschia.

Construction, Expression, and Purification of PI 3-Kinase SH2-GST and SHC-GST Fusion Proteins

Two glutathione S-transferase (GST) fusion proteins containing each of the two SH2 domains of the p85 subunit of PI 3-kinase were constructed using the pGEX-2T plasmid vector (Pharmacia Biotech Inc.) with some modifications in the multiple cloning sites(49) .

Cell Extractions and Immunoprecipitation

To analyze the phosphotyrosine content of receptors from cell extracts, confluent plates were stimulated with 100 ng/ml EGF or heregulin beta2 and extracted in lysis buffer (1% Nonidet P-40, 150 mM NaCl, 50 mM Tris-HCl, pH 7.4, 5 mM EDTA, 5% glycerol, 1 mM sodium orthovanadate). Insoluble material was pelleted by a 5-min microfuge spin, and 5% of a 100 mM plate was boiled in SDS loading buffer. For immunoprecipitations, 2 µl of antiphosphotyrosine antibodies were added (py20-ICN) with 40 µl of a 50% slurry of goat anti-mouse IgG-linked agarose (Sigma), and the mixture was mixed for 60 min at 4 °C. Samples were washed twice with lysis buffer and boiled in SDS sample buffer. Analysis of HER4 protein was done by immunoprecipitating HER4 using a HER4-specific antibody, 6-4-11(12) , and immunoblotted using the same antibody. HER2 protein was analyzed by Western blotting cell extracts with the antibody AB3 anti-HER2 from Oncogene Science, Inc. HER1 immunoprecipitates made use of the AB1 anti-EGFR antibody from Oncogene Science. Antibodies for SHC 06-203, PI 3-kinase 06-195 were purchased from Upstate Biotechnology Inc. (UBI). Anti-EGFR blots were done with antibody 06-129 from UBI. All immunoblotting experiments used I-labeled goat anti-mouse or -rabbit second antibody for detection (DuPont NEN).

In Vitro Kinase Assay

Cells were extracted, and the protein complexes were isolated as described above. After the last wash with lysis buffer, the samples were washed once with kinase buffer (20 mM Tris-HCl, pH 7.4, 5 mM MgCl(2), 150 mM NaCl) and then resuspended in 100 µl of kinase buffer containing 10 µCi of [-P]ATP (DuPont NEN, NEG-002A) and incubated at room temperature for 10 min. The beads were then washed once with kinase buffer and boiled in SDS sample buffer.

Double Precipitation Procedure

In vitro kinased samples were isolated as described except that they were boiled for 2 min in 200 µl of solubilization buffer (0.4% SDS, 50 mM triethanolamine chloride (pH 7.4), 100 mM NaCl, 2 mM EDTA (pH 7.4), and 2 mM 2-mercaptoethanol) instead of SDS sample buffer. The Sepharose beads were then pelleted, the supernatant was recovered, and iodoacetamide (final concentration 10 mM) was added, followed by 0.25 volumes of 10% (v/v) Triton X-100. The extract was then precipitated with antibodies specific for each target and incubated at 4 °C for 60 min (UBI-PI 3-kinase 06-195, SHC-06-203). Protein A-Sepharose CL4B (40 µl of a 50% solution; Pharmacia) was used to precipitate the antibodies. The Sepharose beads were then pelleted, washed twice with lysis buffer, and boiled in SDS sample buffer.

Peptide Inhibition Studies

HER4 was immunoprecipitated and radiolabeled in an in vitro kinase reaction and denatured by boiling in solubilization buffer (0.4% SDS, 50 mM triethanolamine chloride (pH 7.4), 100 mM NaCl, 2 mM EDTA (pH 7.4), and 2 mM 2-mercaptoethanol). GST fusion proteins purified on glutathione-Sepharose beads were used to precipitate HER4 in the absence or presence of 50 µM peptide at 4 °C for 60 min. Complexes were washed in lysis buffer and analyzed by SDS-PAGE. Radiolabeled HER4 was quantified by analysis on a PhosphorImager (Molecular Dynamics).

Peptides

Peptides were synthesized by the solid-phase method on a Gilson multiple peptide synthesizer, model AMS422, using Fmoc amino acids. Phosphotyrosine was incorporated into the peptide either by direct coupling of N-Fmoc-O-phosphotyrosine or by coupling of N-Fmoc-Tyr-OH in a post assembly reaction with di-tert-butyl-diethylphosphoramidite (Aldrich) followed by oxidation with tert-butyl-hydroperoxide. The peptides were cleaved from the resin by reaction with trifluoroacetic acid and purified by reversed-phase high performance liquid chromatography.


RESULTS

HER2 and HER4 Expression and Focal Transforming Activity

To compare the signaling properties of HER4 with that of HER1 and HER2, NIH 3T3 clone 7 cells were transfected with plasmids encoding HER1, HER2, or HER4, resulting in the selection of clonal cell lines. NIH 3T3 clone 7 cells, initially derived from the NIH 3T3 ATCC cell line, are useful in biological assays due to their flatter morphology and ability to remain contact-inhibited when grown to confluence. Immunoprecipitation of cell extracts using receptor-specific antibodies demonstrated that HER1(47) , HER2, and HER4 were overexpressed in the appropriate cell lines (data not shown). HER1, HER2, and HER4 transfectants were seeded onto a monolayer of parental cells and grown in the presence or absence of specific ligand (Fig. 1). Used as a positive control, the HER1-expressing 3T3 clone 7 cell line was able to form foci only when stimulated with EGF. The HER2-expressing cell line was able to form foci in the absence of any added ligand and did not respond to either EGF or heregulin beta2 (50, 51, 52) . HER4-expressing cells were able to form foci in the absence of ligand; however, this activity was further stimulated by the addition of recombinant heregulin beta2. These results demonstrate that HER4 is able to induce cellular transformation similar to that shown for HER1 and HER2.


Figure 1: HER4 focal transforming activity. HER4-transfected cells were mixed with parental NIH 3T3 cells and cultured either in the presence or absence of ligand at a concentration of 20 ng/ml. Cultures were fluid-changed every third day and maintained for 2 weeks. Cell monolayers were stained with a mixture of methylene blue/carboyl fuschia dyes. rHRG, heregulin beta2.



HER4 Tyrosine Phosphorylation

To determine whether heregulin-induced focal transforming activity in HER4 transfectants correlated with an increase in receptor tyrosine phosphorylation, extracts from ligand-stimulated and -unstimulated HER cell lines were denatured, and the levels of tyrosine phosphorylation were analyzed by immunoblot using an antiphosphotyrosine antibody (Fig. 2A). Analysis of extracts in this manner minimizes the impact of protease, phosphatase, and potential autokinase activities that might occur during precipitation. In the HER2 transfectants, the HER2 receptor was constitutively tyrosine-phosphorylated and unresponsive to ligand. The HER4-expressing line demonstrated an elevated level of tyrosine phosphorylation of a 180-kDa protein in the absence of ligand when compared with control 3T3-7 cells; however, phosphorylation could further be induced by exposure to heregulin beta2. Immunoprecipitation of HER4 from extracts with a monoclonal antibody to HER4(6-4-11) confirmed that the band is HER4 (Fig. 2B). Depending upon the extraction conditions, immunoprecipitation of HER4 resulted in the in vitro activation of receptor kinase activity. Lysis buffer containing Mg promoted the in vitro activation of HER4, whereas, in the absence of Mg, HER4 activation was ligand-dependent. The dependence of Mg on HER4 kinase activity is unique to HER4 and has no effect on HER1, HER2, or HER3 (data not shown).


Figure 2: HER4 tyrosine phosphorylation is potentiated by ligand. Cell extracts from control (0) and heregulin beta2-stimulated transfectants (HRG) were boiled immediately in SDS sample buffer and analyzed on SDS-PAGE followed by an antiphosphotyrosine immunoblot (A). Control and heregulin beta2-stimulated HER4-expressing cells were lysed in the presence or absence of Mg, and extracts were precipitated with anti-HER4 6-4-11 followed by analysis in an antiphosphotyrosine immunoblot (B).



HER4 Autokinase Activity

Since HER4 is tyrosine-phosphorylated in response to ligand we set out to determine whether this change in modification correlated with HER4 in vitro autokinase activity. Antiphosphotyrosine immunoprecipitates from HER4 transfectants demonstrated a heregulin beta2-dependent activation of a 180-kDa protein (Fig. 3). This band is HER4, as demonstrated by precipitation using HER4-specific antisera (data not shown). The untransfected control 3T3-7 cell line was not activated by EGF or heregulin beta2, but addition of PDGF stimulated the endogenous PDGF receptor. In contrast to HER1 and HER4, immunoprecipitates from HER2-expressing cells had very little associated kinase activity. This finding was unexpected since we know that HER2 is biologically active (Fig. 1) and is tyrosine-phosphorylated (Fig. 2A). This data identifies that HER4 in vitro kinase activity is activated in response to heregulin beta2. The phosphorylation of receptors is specific to tyrosine residues as determined by resistance to alkaline hydrolysis (data not shown).


Figure 3: HER4 in vitro kinase activity. Antiphosphotyrosine immunoprecipitates of control and ligand-stimulated cell lines were assayed in an in vitro kinase reaction. P-Labeled receptor complexes were analyzed on SDS-PAGE and visualized by exposure to a PhosphorImager screen. The arrow points to radiolabeled receptor.



HER4 Association with PI 3-Kinase and SHC

The signaling through growth factor receptors results in the phosphorylation of downstream targets. We set out to identify HER4-associated targets and to determine if there were differences in signaling between HER4 and that of other HER family members. In vitroP-labeled antiphosphotyrosine immune complexes were denatured, and the target of interest was reimmunoprecipitated with specific antibodies. Heregulin beta2 stimulation of cells expressing HER4 were found to be associated with an increased level of tyrosine-phosphorylated p85, the regulatory subunit of the PI 3-kinase (Fig. 4A), as well as all splicing variants of SHC (Fig. 4B). Similar results were obtained when the initial precipitation was performed with antibody specific for HER4, demonstrating a physical association between HER4 and both PI-3 kinase and SHC (data not shown). EGF stimulation of HER1 induced the phosphorylation of SHC but not 85-kDa PI 3-kinase. HER2-expressing cells did not demonstrate any inducible activation of 85-kDa PI 3-kinase or SHC. In the untransfected control cell line, stimulation with PDGF, but not EGF and heregulin beta2, resulted in the activation of 85-kDa PI 3-kinase, reflecting the activation of the endogenous mouse PDGF receptor. There was a detectable activation of SHC by EGF in the parental cell line, possibly due to low level activation of the endogenous mouse EGF receptor.


Figure 4: HER4 can associate with SHC and PI 3-kinase. A, antiphosphotyrosine immunoprecipitates from control and ligand-stimulated cell lines were labeled in an in vitro kinase assay. Labeled complexes were denatured by boiling in solubilization buffer, and 85-kDa PI 3-kinase (A) and SHC (B) were reimmunoprecipitated with specific antisera. Purified immune complexes were analyzed on SDS-PAGE, and gels were dried down and exposed on a PhosphorImager screen.



Identification of PI 3-Kinase and SHC Binding Sites

HER4 contains a single putative binding site for PI 3-kinase (YTPM) at amino acid 1056 and three potential SHC binding sites (NPXY) at amino acids 1188, 1242, and 1284. To investigate whether or not these sites mediate interaction with these targets, phosphotyrosine-containing peptides correlating to these sequences were synthesized and used to inhibit the in vitro binding of PI 3-kinase and SHC to HER4 (Fig. 5A). GST was fused to the N- and C-terminal SH2 domains of PI 3-kinase and full-length SHC and used to precipitate HER4. Peptide 1056, which includes the PI 3-kinase binding motif, was able to inhibit the binding of both PI 3-kinase SH2 fusions to HER4 (Fig. 5B). No inhibition was seen when the unphosphorylated control peptide (1056Y) was used, nor with other peptides containing NPXY motifs. The GST-SHC fusion was also able to associate with HER4, and this binding was inhibited 74% by peptide 1188 and 91% by peptide 1242. These data suggest that there may be two SHC binding sites on HER4 and that 1242 is the primary site. In addition, peptide 1284, which also contains an NPXY motif, did not compete. This demonstrates that sequences adjacent to NPXY must be important for SHC recognition of the receptor.


Figure 5: Identification of the PI 3-kinase and SHC binding sites on HER4. A, peptides were synthesized corresponding to potential tyrosine phosphorylation sites within the C-terminal domain of HER4. The peptide number correlates with the amino acid number of the tyrosine residue. The underlined sequences represent potential PI 3-kinase or SHC binding motifs. B, immunoprecipitated HER4 was radiolabeled in an in vitro kinase assay and denatured by boiling in solubilization buffer. Denatured HER4 was then reprecipitated using GST fusions of PI 3-kinase N- and C-terminal SH2 domains and full-length SHC. Peptides corresponding to regions of HER4 were added at a concentration of 50 µM with the GST fusions during the precipitation. Complexes were boiled in SDS sample buffer and analyzed by SDS-PAGE.



Heterodimerization between HER4 and HER1

It has previously been demonstrated that certain members of the HER family of receptors can heterodimerize with one another(15, 27, 28, 29, 30, 31) . We set out to determine whether or not HER4 was able to heterodimerize with HER1. The first indication that HER1 and HER4 could functionally interact was demonstrated in a growth in soft agar assay. 3T3- and 3T3/HER4-transfected cell lines were plated in agar in the presence of heregulin beta2 or EGF. The control 3T3 cells did not form colonies under any condition, whereas the HER4 expressing cells formed colonies in response to both heregulin beta2 and EGF (Fig. 6).


Figure 6: EGF and heregulin beta2 induce colony growth in soft agar. HER4-transfected cells were plated either in the presence or absence of EGF or heregulin beta2 at a concentration of 100 ng/ml in 0.4% agar. Cultures were allowed to grow for 3 weeks and photographed directly.



If HER1 and HER4 can functionally interact and elicit a growth response, then stimulation with the appropriate ligand might result in cross-phosphorylation of one receptor by the other. Stimulation of parental 3T3 cells resulted in increased tyrosine phosphorylation of mouse EGFR in response to EGF but not heregulin (Fig. 7A). However, in cells transfected with HER4, tyrosine phosphorylation of the endogenous EGFR was elevated in the absence of ligand and further increased in response to both EGF and heregulin beta2. Increasing the level of EGFR expression also increased the level of heregulin beta2-induced EGFR tyrosine phosphorylation. In contrast, there was no detectable increase in HER4 phosphorylation in response to EGF (Fig. 7B). These results suggest that HER1 and HER4 can exist in a heterodimer complex and that transphosphorylation can occur in one direction, in that activation of HER4 results in the phosphorylation of HER1 but HER4 is not a substrate for HER1.


Figure 7: Complex formation between HER1 and HER4. NIH 3T3 cells expressing HER1, HER4, or both were stimulated with either EGF or heregulin beta2. Receptors were immunoprecipitated following cell lysis and analyzed on SDS-PAGE followed by transfer onto nitrocellulose. The blot was probed with the indicated antibody followed by I-labeled protein A.




DISCUSSION

The activation of HER family members, as well as their respective signaling through downstream targets is different for each receptor. Further, the complexity of these signaling pathways becomes even more diverse due to receptor heterodimerization, which may alter the specificity or strength of response to a given ligand. It has been demonstrated that HER1, HER2, and HER3 can interact with one another (15, 27, 28, 29, 30, 31) . It has also been shown that HER4 activation can result in the phosphorylation of HER2. In this paper, we describe some of the properties of HER4 that are similar and different from those of other family members. We were able to demonstrate that HER4 can also complex with HER1, resulting in an enhanced growth signal in agar in response to EGF and the transphosphorylation of EGFR by HER4 in response to heregulin beta2. The endogenous level of EGFR tyrosine phosphorylation was elevated in cells co-expressing HER4, suggesting that the heterodimer may exist at low levels in the absence of ligand. Increasing the level of EGFR by transfecting HER1 resulted in a higher level of both ligand-independent and heregulin-stimulated HER1 phosphorylation, suggesting that the stoichiometry of receptor heterodimers is dependent upon receptor expression levels. We did not observe an EGF-dependent phosphorylation of HER4, which suggests that HER4 is not a substrate for HER1. Nevertheless, EGF could induce colony formation in cells expressing HER4, which suggests that a HER1-HER4 complex is being formed. It remains to be investigated whether or not HER4 and HER3 can form a complex that would complete the possible combinations of currently known HER family member heterodimerizations.

Biologically, we have shown that HER4 can stimulate 3T3 cells to grow and overcome cell-to-cell contact inhibition at a low level in the absence of exogenous ligand and that this activity can be further induced by the addition of heregulin beta2 but not EGF. Conversely, both heregulin beta2 and EGF were able to induce the growth of colonies in soft agar in HER4-expressing cells but not the control NIH 3T3 cells. It is unclear why there is a difference in EGF responsiveness between the focal transformation assay and the agar assay. Perhaps the heterodimer complex is providing the necessary downstream signals needed for growth in soft agar but not the signals needed to overcome contact inhibition.

In analyzing HER4 tyrosine phosphorylation in rapidly denatured extracts, HER4 is slightly phosphorylated in the absence of ligand and can be further induced by the addition of heregulin beta2. Immunoprecipitation of HER4 in the presence of Mg results in the in vitro stimulation of HER4 tyrosine phosphorylation and stimulation of HER4 in vitro kinase activity. This activation, in the absence of ligand, is likely a result of concentrating the receptor by immunoprecipitation and is unique to HER4, for it does not occur with HER1, HER2, and HER3. Removal of Mg from the lysis buffer restores ligand responsiveness to our biochemical analysis. While HER1 and HER4 are both ligand-responsive, HER2 is constitutively hyperphosphorylated.

The in vitro kinase activity associated with these receptors provided a means to identify downstream targets activated by these receptors. HER4 was able to induce the phosphorylation of both SHC and 85-kDa PI 3-kinase. HER1 could activate SHC but not 85-kDa PI 3-kinase, which identifies a divergence of activities between HER1 and HER4. HER2 kinase activity and subsequent association with downstream targets could not be determined due to the lack of in vitro kinase activity associated with the receptor. HER2 is constitutively tyrosine-phosphorylated and appears to associate with downstream targets in other types of assays(43, 44, 45, 53, 54) . The lack of HER2 in vitro kinase activity remains to be investigated.

The association of SH2-containing proteins with growth factor receptors is integral in transmitting growth-stimulatory signals. The elements required for the association of SH2-containing proteins to tyrosine kinases involve a phosphorylated tyrosine residue flanked by specific sequences. Specifically, YXXM (34) and NPXY (37) are essential motifs for the binding of PI 3-kinase and SHC, respectively, to their target kinases. The C-terminal domain of HER4 contains one YXXM motif (YTMP). Peptide 1056, corresponding to this motif, was able to inhibit binding of both N- and C-terminal PI 3-kinase SH2 domains. HER1 does not contain a YXXM motif in its C terminus, which correlates with the inability to phosphorylate the 85-kDa subunit of PI 3-kinase in our assay. These data confirm the essential nature of the YXXM motif in HER4 for binding PI 3-kinase and that each of the PI 3-kinase SH2 domains alone is sufficient for association with HER4.

HER4 contains three potential SHC binding sites (NPXY) within its C-terminal coding sequence located at amino acids 1188, 1242, and 1284. Full-length SHC was able to form a complex with HER4, and this interaction was inhibited by peptides 1188 and 1242. This suggests that there are two potential SHC binding sites on HER4. Recent observations have identified a second motif in the N-terminal portion of SHC, distinct from the SH2, that is able to associate with tyrosine-phosphorylated EGFR (55) and a SHC-associated protein, p145 (56) . Identification of the domain within SHC required to associate with HER4 is under investigation.

The relationship between the HER family of receptors and their ability to respond to similar ligands resulting in both homo- and heterodimerized complexes lends itself to a very complex system of cell signaling. Since multiple HER members are often expressed concomitantly, the specific combination and relative level of expression of different receptors will determine the response to a given ligand. This is evident in human tumor cell lines in which heregulin can induce either a mitogenic (21, 57) or a terminally differentiating signal(17) , depending upon the cell type. Thus, altering the pattern of expression of HER family members may offer a selective growth advantage during tumor progression in the presence of HER family ligands. It has been shown that overexpression of several EGF-like growth factors, such as transforming growth factor alpha, amphiregulin, and cripto-1, represents a hallmark feature of many solid tumors. A better understanding of the downstream signals produced from both receptor homo- and heterodimers, as well as the ligands involved, is critical to a better understanding of the biology of HER family signal transduction and its role in tumor progression.


FOOTNOTES

*
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: Molecular Immunology Dept., Bristol-Myers Squibb, Pharmaceutical Research Institute, 3005 First Ave., Seattle, WA 98121. Tel: 206-727-3559; Fax: 206-727-3603.

(^1)
The abbreviations used are: HER, human epidermal growth factor receptor; EGF, epidermal growth factor; EGFR, EGF receptor; PI, phosphatidylinositol; GST, glutathione S-transferase; Fmoc, N-(9-fluorenyl)methoxycarbonyl; PDGF, platelet-derived growth factor; SH2, Src homology region 2; PAGE, polyacrylamide gel electrophoresis.


ACKNOWLEDGEMENTS

We thank Jim Blake for synthesis and purification of the phosphotyrosine peptides, Jean-Michel Culouscou and Gary Carlton for providing heregulin beta2, Brian Schaffhausen for the SHC GST construct, Greg Plowman for discussion, Bill Vass for providing the 3T3/ER cells, Ursula Garrigues for providing the HER4 antibodies, and Clay Siegall for helpful discussion and support.


REFERENCES

  1. Khazaie, K., Schirrmacher, V., and Lichtner, R. B. (1993) Cancer Metastasis Rev. 12, 255-274 [Medline] [Order article via Infotrieve]
  2. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. (1987) Science 234, 177-181
  3. Kraus, M. H., Popescu, N. C., Amsbaugh, S. C., and King, C. R. (1987) EMBO J. 6, 605-610 [Abstract]
  4. Berchuck, A., Kamel, A., Whitaker, R., Kerns, B., Olt, G., Kinney, R., Soper, J. T., Dodge, R., Clarke-Pearson, D. L., Marks, P., McKenzie, S., Yin, S., and Bast, R. C., Jr. (1990) Cancer Res. 50, 4087-4091 [Abstract]
  5. Giovanella, B. C., Vardeman, D. M., Williams, L. J., Taylor, D. J., De Ipolyi, P. D., Greef, P. J., Stehlin, J. S., Ullrich, A., Cailleau, R., Slamon, D. J., and Gary, H. E., Jr. (1991) Int. J. Cancer 47, 66-71 [Medline] [Order article via Infotrieve]
  6. O'Reilly, S. M., Barnes, D. M., Camplejohn, R. S., Bartkova, J., Gregory, W. M., and Richards, M. A. (1991) Br. J. Cancer 63, 444-446 [Medline] [Order article via Infotrieve]
  7. Gullick, W. J., Love, S. B., Wright, C., Barnes, D. M., Gusterson, B., Harris, A. L., and Altman, D. G. (1991) Br. J. Cancer 63, 434-438 [Medline] [Order article via Infotrieve]
  8. Kraus, M. H., Issing, W., Miki, T., Popescu, N. C., and Aaronson, S. A. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 9193-91978 [Abstract]
  9. Lemoine, N. R., Barnes, D. M., Hollywood, D. P., Hughes, C. M., Smith, P., Dublin, E., Prigent, S. A., Gullick, W. J., and Hurst, H. C. (1992) Br. J. Cancer 66, 1116-1121 [Medline] [Order article via Infotrieve]
  10. Kraus, M. H., Fedi, P., Starks, V., Muraro, R., and Aaronson, S. A. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 2900-2904 [Abstract]
  11. Skinner, A., and Hurst, H. C. (1993) Oncogene 8, 3396-3401
  12. Siegall, C. B., Bacus, S. B., Cohen, B. D., Plowman, G. D., Mixan, B., Chace, D., Chin, D. M., Goetze, A., Green, J. M., Hellstrom, I., Hellstrom, K. E., and Fell, H. P. (1995) J. Biol. Chem. 270, 7625-7630 [Abstract/Free Full Text]
  13. Schlessinger, J., and Ullrich, A. (1992) Neuron 9, 383-391 [Medline] [Order article via Infotrieve]
  14. Carpenter, G., and Cohen, S. (1979) Annu. Rev. Biochem. 48, 193-216 [CrossRef][Medline] [Order article via Infotrieve]
  15. Plowman, G. D., Green, J. M., Culouscou, J-M., Carlton, G. W., Rothwell, V. M., and Buckley, S. (1993) Nature 366, 473-475 [CrossRef][Medline] [Order article via Infotrieve]
  16. Sliwkowski, M. X., Schaefer, G., Akita, R. W., Lofgren, J. A., Fitzpatrick, V. D., Nuijens, A., Fendly, B. M., Cerione, R. A., Vandlen, R. L., and Carraway, K. L., III (1994) J. Biol. Chem. 269, 14661-14665 [Abstract/Free Full Text]
  17. Peles, E., Bacus, S. S., Koski, R. A., Lu, H. S., Wen, D., Ogden, S. G., Ben-Levy, R. B., and Yarden, Y. (1992) Cell 69, 205-216 [Medline] [Order article via Infotrieve]
  18. Tzahar, E., Levkowitz, G., Karunagaran, D., Yi, L., Peles, E., Lavi, S., Chang, D., Liu, N., Yayon, A., Wen, D., and Yarden, Y. (1994) J. Biol. Chem. 269, 25226-25233 [Abstract/Free Full Text]
  19. Peles, E., Ben-Levy, R., Tzahar, E., Liu, N., Wen, D., and Yarden, Y. (1993) EMBO J. 12, 961-971 [Abstract]
  20. Bacus, S. S., Huberman, E., Chin, D., Kiguchi, K., Simpson, S., Lippman, M., and Lupu, R. (1992) Cell Growth & Differ. 3, 401-411
  21. Marchionni, M. A., Goodearl, A. D. J., Chen, M. S., Bermingham-McDonough, O., Kirk, C., Hendricks, M., Danehy, F., Misumi, D., Sudhalter, J., Kobayashi, K., Wroblewski, D., Lynch, C., Baldassare, M., Hiles, I., Davis, J. B., Husan, J. J., Totty, N. F., Otsu, M., McBurney, R. N., Waterfield, M. D., Stroobant, P., and Gwynne, D. (1993) Nature 362, 312-318 [CrossRef][Medline] [Order article via Infotrieve]
  22. Falls, D. L., Rosen, K. M., Corfas, G., Lane, W. S., and Fischbach, G. D. (1993) Cell 72, 801-815 [Medline] [Order article via Infotrieve]
  23. Lupu, R., Colomer, R., Kannan, B., and Lippman, M. E. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 2287-2291 [Abstract]
  24. Huang, S. S., and Huang, J. S. (1992) J. Biol. Chem. 267, 11508-11512 [Abstract/Free Full Text]
  25. Samanta, A., LeVea, C. M., Dougall, W. C., Qian, X., and Greene, M. I. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 1711-1715 [Abstract]
  26. Carraway, K. L., III, Sliwkowski, M. X., Akita, R., Platko, J. V., Guy, P. M., Nuijens, A., Diamonti, A. J., Vandlen, R. L., Cantley, L. C., and Cerione, R. A. (1994) J. Biol. Chem. 269, 14303-14306 [Abstract/Free Full Text]
  27. King, C. R., Borrello, I., Bellot, F., Comoglio, P., and Schlessinger, J. (1988) EMBO J. 7, 1647-1651 [Abstract]
  28. Akiyama, T., Saito, T., Ogawara, H., Toyoshima, K., and Yamamoto, T. (1988) Mol. Cell. Biol. 8, 1019-1026 [Medline] [Order article via Infotrieve]
  29. Goldman, R., Levy, R. B., Peles, E., and Yarden, Y. (1990) Biochemistry 29, 11024-11028 [Medline] [Order article via Infotrieve]
  30. Wada, T., Qian, X., and Greene, M. I. (1990) Cell 61, 1339-1347 [Medline] [Order article via Infotrieve]
  31. Soltoff, S. P., Carraway, K. L., III, Prigent, A., Gullick, W. G., and Cantley, L. C. (1994) Mol. Cell. Biol. 14, 3550-3558 [Abstract]
  32. Koch, C. A., Anderson, D., Moran, M. F., Ellis, C., and Pawson, T. (1991) Science 252, 668-674 [Medline] [Order article via Infotrieve]
  33. Songyang, Z., Shoelson, S. E., Chaudhuri, M., Gish, G., Pawson, T., Haser, W. G., King, F., Roberts, T., Ratnofsky, S., Lechleider, R. J., Neel, B. G., Birge, R. B., Fajardo, J. E., Chou, M. M., Hanafusa, H., Schaffhausen, B., and Cantley, L. C. (1993) Cell 72, 767-778 [Medline] [Order article via Infotrieve]
  34. Cantley, L. C., Auger, K. R., Carpenter, C., Duckworth, B., Graziani, A., Kapeller, R., and Soltoff, S. (1991) Cell 64, 281-302 [Medline] [Order article via Infotrieve]
  35. Pawson, T., and Gish, G. D. (1992) Cell 71, 359-362 [Medline] [Order article via Infotrieve]
  36. Mayer, B. J., and Baltimore, D. (1993) Trends Cell Biol. 3, 8-13 [CrossRef]
  37. Campbell, K. S., Ogris, E., Burke, B., Su, W., Auger, K. R., Druker, B. J., Schaffhausen, B. S., Roberts, T. M., and Pallas, D. C. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 6344-6348 [Abstract]
  38. Pelicci, G., Lanfrancone, L., Grignani, F., McGlade, J., Cavallo, F., Forni, G., Nicoletti, I., Pawson, T., and Pelicci, P. G. (1992) Cell 70, 93-104 [Medline] [Order article via Infotrieve]
  39. Meisenhelder, J., Suh, P-G., Rhee, S. G., and Hunter, T. (1989) Cell 57, 1109-1122 [Medline] [Order article via Infotrieve]
  40. Margolis, B., Rhee, S. G., Felder, S., Mervic, M., Lyall, R., Levitzki, A., Ullrich, A., Zilberstein, A., and Schlessinger, J. (1989) Cell 57, 1101-1107 [Medline] [Order article via Infotrieve]
  41. Wahl, M. I., Nishibe, S., Suh, P-G., Rhee, S. G., and Carpenter, G. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 1568-1572 [Abstract]
  42. Fedi, P., Pierce, J. H., Di Fiore, P. P., and Kraus, M. H. (1994) Mol. Cell. Biol. 14, 492-500 [Abstract]
  43. Di Fiore, P. P., Segatto, O., Taylor, W. G., Aaronson, S. A., and Pierce, J. H. (1990) Science 248, 79-83 [Medline] [Order article via Infotrieve]
  44. Jallal, B., Schlessinger, J., and Ullrich, A. (1992) J. Biol. Chem. 267, 4357-4363 [Abstract/Free Full Text]
  45. Segatto, O., Pelicci, G., Giuli, S., Digiesi, G., Di Fiore, P. P., McGlade, J., Pawson, T., and Pelicci, P. G. (1993) Oncogene 8, 2105-2112 [Medline] [Order article via Infotrieve]
  46. Kim, H-H., Sierke, S. L., and Koland, J. G. (1994) J. Biol. Chem. 269, 24747-24755 [Abstract/Free Full Text]
  47. Martin, P., Vass, W. C., Schiller, J. T., Lowy, D. R., and Velu, T. J. (1989) Cell 59, 21-32 [Medline] [Order article via Infotrieve]
  48. Culouscou, J-M., Carlton, G. W., and Aruffo, A. (1995) J. Biol. Chem. 270, 12857-12863 [Abstract/Free Full Text]
  49. Chalupny, N. J., Aruffo, A., Esselstyn, J. M., Chan, P. Y., Blake, J., Gilliland, L. K., Ledbetter, J. A., and Tepper, M. A. (1995) Eur. J. Immunol. 25, 2978-2984 [Medline] [Order article via Infotrieve]
  50. Di Fiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., and Aaronson, S. A. (1987) Science 237, 178-182 [Medline] [Order article via Infotrieve]
  51. Di Fiore, P. P., Pierce, J. H., Fleming, T. P., Hazan, R., Ullrich, A., King, C. R., Schlessinger, J., and Aaronson, S. A. (1987) Cell 51, 1063-1070 [Medline] [Order article via Infotrieve]
  52. Hudziak, R. M., Schlessinger, J., and Ullrich, A. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 7159-7163 [Abstract]
  53. Pierce, J. H., Ruggiero, M., Fleming, T. P., Di Fiore, P. P., Greenberger, J. S., Varticovski, L., Schlessinger, J., Rovera, G., and Aaronson, S. A. (1988) Science 239, 628-631 [Medline] [Order article via Infotrieve]
  54. Fazioli, F., Kim, U-H., Rhee, S. G., Molloy, C. J., Segatto, O., and Di Fiore, P. P. (1991) Mol. Cell. Biol. 11, 2040-2048 [Medline] [Order article via Infotrieve]
  55. Blaikie, P., Immanuel, D., Wu, J., Li, N., Yajnik, V., and Margolis, B. (1994) J. Biol. Chem. 269, 32031-32034 [Abstract/Free Full Text]
  56. Kavanaugh, W. M., and Williams, L. T. (1994) Science 266, 1862-1865 [Medline] [Order article via Infotrieve]
  57. Holmes, W. E., Sliwkowski, M. X., Akita, R. W., Henzel, W. J., Lee, J., Park, J. W., Yansura, D., Adabi, N., Raab, H., Lewis, G. D., Shepard, H. M., Kuang, W-J., Wood, W. I., Goeddel, D. V., and Vandlen, R. L. (1992) Science 256, 1205-1210 [Medline] [Order article via Infotrieve]
  58. Heldin, C-H. (1995) Cell 80, 213-223 [Medline] [Order article via Infotrieve]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.